12. Iron Dextran
13. Isosorside Dinitrate
14. Ketroprofen
15. Loperamide
16. Oxythazine
17. Pentazocine
18. Piperazine
19. Sulphamathizole
20. Salazosulphapyrazine
21. Sulphadoxine
22. Triemterene
23. Verapamil
24. Neomycin
25. Thicridazine
26. Amtriptyline
27. Trifluperazine
28. Triprolodine
29. Trimipramine
30. Polyixin B. Sulphate
31. Glipizide
32. Pyrithyldione
33. Zinc Bacitracin
34. Mitomycin
35. Tolnafatate
36. Fluocinolone Acetonide
37. Carbenicillin Sodium
38. Oxyfedrine HC1.
39. Hyoscine N-Butyi Bromide
40. Triamlinolone
41. Naproxen
42. Pyrithioxine
43. L-Dopa
44. Norgesterol
45. Ethisterone
46. Carbenixclone
47. Renerpine
48. Amoxycillin
49(a) Ampicillin Trihydrate
49(b). Ampicilin Anhydrous
50. Doxycycline
51. Diphenoxylate
52. Hydralazine
53. Metoclopramide
54. Nalidixic Acid
55. Promethazine HC1.
56. Metroprolol
57. Chlorpromazine
58. Timolol
59. Emipramihe
60. Povidone Iodine
61. Cimetidine
62. Ranitidine

Auditing receipts and payments of DiPEA

2254. CHOWDHARY RAM SEWAK:

SHRl SANTOSH KUMAR SAHU;

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Government have received Audit objections on the expected receipts and payments into the DPEA received by the Ministry during the last three years;

(b) if so, the details thereof;

(c) when were these objections received;

(d) whether it is a fact that people engaged in the work of audit were influenced to withdraw the objections and also not to scrutinise full facts, during th$_e$ past thre$_e$ years;

(e) whether the records asked for by those people were not made avail-

able to them and they also did not pursue the matter due to the considerations received by them; and

(f) what steps have been taken to order full investigation of the matter?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN); (a) to (f) The details regarding the amounts recoverable from the various drug companies as assessed by the Government on a tentative basis, have been submitted to the House from time to time in reply to a number of Questions. The reasons on account of which the re. covery has been of only a meagre amount have also been indicated which include, the pendency of the Writ Petitions filed by the companies concerned, *inter alia,* challenging the correctness, justification and legality of the liabilities worked out by the Government. All relevant records including these papers are av. ailable for audit inspection. The audit have already been informed *vide* this Ministry's letter of 22nd January, 1992 to discuss the matter with the officers of this Department. The discussion has not yet taken place.

Non processing of writ petitions

2255. SHRI SANTOSH KUMAR SAHU-
CHOWDHARY RAM SEWAK:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 3104 given in the Rajya Sabha on 19th December, 1991 and state;

(a) whether it is a fact that writ petitions filed by several companies are not processed for years and allowed to die their own death in his Ministry;

(b) what are the details such as name, product, issues involved and decision in each case where the writ wag filed by each company from the inception of DPCO, 1979; and

(c) whether the decision of the court has been fully complied with and if not, what are the reasons for
the same:

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b) T_0 the extent information is available, the details asked for in the question are given in the An nexure.

(See Appendix CLXII, Annexure No. 52).

(c) The determination of the final liabilities of the companies, in terms of the judgement of the Courts is still in progress.

Crossing limits by Mls. Carews sales turn over

2256. SHRI ASHOK NATH VERMA:
SHRI H. HANUMAN-THAPPA;

Will the PRIME MINISTER be pleased to refer to the answer to unstarred question 3115 given in Rajya Sabha on 19-12.1991 and state:

(a) whether it is a fact that M[s. Carews crossed the limit of Rs. 50 lakhs in sales turn over in 1984;

(b) whether it is a fact that they extracharged the public by Rs. 9.51 for Alcagel Tablet and by Rs. 0.39 in respect of Orelegin tablets to the consumer for over three years in connivance with the Assistant Development Commissioner (PI); and

(c) when was each application of Combiflame, Alcagel and Carelepin submitted to Government for price approval and when did the company implement Government fixed price in each case?